Halina Offner
Founder at Artielle ImmunoTherapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gilbert N. Miller | M | - |
Artielle ImmunoTherapeutics, Inc.
 Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 23 years |
| Peter C. M. McWilliams | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Arthur A. Vandenbark | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 years |
| Peter O. Kohler | M | 85 |
Oregon Health & Science University
| 36 years |
| Brock Metcalf | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Brian Druker | M | 68 |
Oregon Health & Science University
| 31 years |
| Rick L. Bentzinger | M | - |
Oregon Health & Science University
| 19 years |
| Vincent Price | M | 60 |
Oregon Health & Science University
| - |
| Jessica Castle | M | - |
Oregon Health & Science University
| - |
| Derick Vivier | M | - |
Oregon Health & Science University
| - |
| Daisy Alva | F | - |
Oregon Health & Science University
| - |
| Erik Brodt | M | - |
Oregon Health & Science University
| - |
| Kristen Beiers-Jones | F | - |
Oregon Health & Science University
| - |
| Michael C. Heinrich | M | - |
Oregon Health & Science University
| - |
| Rose McPharlin | F | - |
Oregon Health & Science University
| - |
| Stefanie Petrie | F | - |
Oregon Health & Science University
| - |
| Dennis Koop | M | - |
Oregon Health & Science University
| - |
| Aaron Nilsen | M | - |
Oregon Health & Science University
| - |
| Lev Fedorov | M | - |
Oregon Health & Science University
| - |
| Kellie Guentert | F | - |
Oregon Health & Science University
| - |
| Cary O. Harding | M | - |
Oregon Health & Science University
| 25 years |
| Misha Pavel | M | - |
Oregon Health & Science University
| - |
| Tomasz Beer | M | - |
Oregon Health & Science University
| - |
| Matthew C. Riddle | M | - |
Oregon Health & Science University
| - |
| David E. Battaglia | M | - |
Oregon Health & Science University
| - |
| Holly Jimison | M | - |
Oregon Health & Science University
| - |
| Nancy Press | M | - |
Oregon Health & Science University
| - |
| Yong Hong Yan | M | 57 |
Oregon Health & Science University
| - |
| Shahab Fatheazam | M | 72 |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 years |
| Christopher Dubay | M | - |
Oregon Health & Science University
| - |
| Erwin Schwarz | M | - |
Oregon Health & Science University
| 25 years |
| William Thoma | M | - |
Oregon Health & Science University
| - |
| Mary H. Oldshue | F | 72 |
Oregon Health & Science University
| - |
| Michael McLean | M | - |
Oregon Health & Science University
| - |
| Rocky Dixon | M | - |
Oregon Health & Science University
| - |
| Henry Hollis Hewitt | M | 82 |
Oregon Health & Science University
| - |
| Chad Waite | M | 69 |
Oregon Health & Science University
| - |
| Scott Hansen | M | - |
Oregon Health & Science University
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Adolph J. Ferro | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Gregory G. Burrows | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Andrew S. Goldstein | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 41 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Halina Offner
- Personal Network
